文献速递胸部肿瘤

妊娠期ALK重排NSCLC快速进展:阿来替尼联合铂类-紫杉化疗后成功妊娠

Brief Report: Alectinib With Salvage Platinum-Taxane Chemotherapy in a Pregnant Woman With ALK-Rearranged NSCLC and Rapid Disease Progression Followed by a Successful Pregnancy.
PubMed 文献 · J Thorac Oncol · 2025-11-20

一例29岁转移性ALK重排NSCLC女性在阿来替尼治疗期间妊娠,孕24周出现快速全身进展,加用卡铂和紫杉醇化疗后好转,孕34+5周择期剖宫产分娩,婴儿9月龄发育正常。产后换用劳拉替尼联合培美曲塞,虽获完全代谢缓解但数月后进展,初诊后28个月死亡。胎盘分析提示胎儿生长受限特征,线粒体功能正常。

要点

  • 妊娠期ALK重排NSCLC在阿来替尼治疗中可发生快速全身进展,需多学科团队个体化管理。
  • 妊娠期加用卡铂和紫杉醇化疗后患者反应良好并成功分娩,婴儿9月龄发育正常。
  • 胎盘分析提示胎儿生长受限特征,但线粒体功能正常。

核心结论

  • 首例报道妊娠期阿来替尼联合细胞毒化疗用于进展性ALK重排NSCLC,显示妊娠期强化全身治疗潜在可行且安全。
  • 胎盘表现与胎儿生长受限妊娠中的观察一致。

研究设计与样本

  • 简要报告:多学科团队临床管理、阿来替尼药代动力学分析及产后胎盘检查(组织病理学和线粒体呼吸功能评估)。
  • 研究对象为1例29岁转移性ALK重排NSCLC女性,在阿来替尼治疗期间妊娠。

主要发现

  • 孕24周出现快速全身进展,表现为消耗性心内膜炎伴多区域小脑梗死、血小板减少、D-二聚体升高及两处大脑中动脉大面积缺血性卒中,需血管内取栓。
  • 加用卡铂和紫杉醇化疗后反应良好,孕34+5周择期剖宫产成功分娩。
  • 产后换用劳拉替尼联合培美曲塞,获完全代谢缓解,但数月后进展,初诊后28个月死亡。
  • 胎盘分析显示胎儿生长受限特征,线粒体功能在正常范围内,尽管胎盘形态有改变。
  • 婴儿9月龄时发育正常。

临床怎么用

  • 妊娠期ALK重排NSCLC进展时,可考虑在多学科团队指导下强化全身治疗,包括阿来替尼联合铂类-紫杉化疗。
  • 需关注胎盘健康和胎儿生长情况,产后进行胎盘病理及功能评估。

局限性

  • 单例病例报告,结论不能推广至所有妊娠期ALK重排NSCLC患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: ALK-rearranged NSCLC is a distinct molecular subtype that disproportionally affects younger never-smoking females, which overlaps with the reproductive age group. Alectinib is a second-generation ALK inhibitor and is generally considered a safer option during pregnancy compared with lorlatinib. Here, we describe a case of a patient who became pregnant while on alectinib complicated by rapid disease progression, with a focus on maternal-fetal outcomes and placental health. METHODS: A brief report was conducted detailing clinical management by a multidisciplinary team, pharmacokinetic analysis of alectinib levels, and post-delivery placental examination, including histopathology and mitochondrial respirometry function assessment as an indicator of placental health. RESULTS: A 29-year-old woman with metastatic ALK-rearranged NSCLC became pregnant while on alectinib therapy. At 24 weeks of gestation, she experienced rapid systemic disease progression manifesting as marantic endocarditis with multi-territory small cerebral infarcts, thrombocytopenia, an elevated D-dimer level, and development of two large middle cerebral ischemic strokes requiring endovascular clot retrieval. Carboplatin and paclitaxel chemotherapy was added to alectinib. The patient responded well to the treatment and successfully delivered an infant through elective caesarean section at 34+5 weeks. The patient was switched to lorlatinib plus pemetrexed postpartum. Although she achieved a complete metabolic response with lorlatinib plus pemetrexed, disease progression occurred after several months, and she died 28 months after initial diagnosis. Placental analysis revealed features indicative of fetal growth restriction. Mitochondrial function appeared within normal limits, despite changes in placental morphology. The infant has shown normal development at 9 months of age. CONCLUSIONS: This is the first reported case of concurrent alectinib and cytotoxic chemotherapy during pregnancy, successfully used in the setting of progressive ALK-rearranged NSCLC. The placental findings align with observations in pregnancies complicated by fetal growth restriction. This case highlights the potential feasibility and safety of intensification of systemic therapy during pregnancy and underscores the importance of individualized multidisciplinary care.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Pham R, Garama D, Malhotra A, et al. Brief Report: Alectinib With Salvage Platinum-Taxane Chemotherapy in a Pregnant Woman With ALK-Rearranged NSCLC and Rapid Disease Progression Followed by a Successful Pregnancy. J Thorac Oncol. 2025. PMID: 41274414. doi:10.1016/j.jtho.2025.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。